Additionally, unfavorable side effect profiles of pan-inhibitors arise from HDAC isoenzymes possessing toxic effects on non-tumor cells, mainly through the inhibition of HDAC 1, 2, and 3 leading to the dose limitation of pan-HDAC inhibitors [9]. This evidence concerns the gene HDAC9 and neoplasm.